Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox vs conventional surgery for acquired esotropia
2020-000280-23Phase 3Active
- Sponsor
- Prof Mathias Abegg
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of botulinum toxin type A in Acquired esotropia, strabismus and Esotropia (ET) (2 arms), sponsored by Prof Mathias Abegg. Primary endpoint: Binocular vision at 18 months. Started Jul 2020; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
Acquired esotropiastrabismusEsotropia (ET)
Beyond the preview
Go deeper on 2020-000280-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000280-23.